Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cord blood cells aim to speed platelet recovery in transplant patients

NCT ID NCT07696767

Not yet recruiting Disease control Sponsor: Anhui Provincial Hospital Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This early study tests an experimental cell therapy called MegaLT, made from umbilical cord blood cells, to help restore platelet levels faster after a cord blood transplant. Adults with blood cancers who receive a cord blood transplant will get a single infusion of MegaLT two weeks later. The goal is to see if it safely reduces the time to platelet recovery and the need for platelet transfusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MegaLT Injection (megakaryocyte cell product from cord blood)
What this could lead to
If it works, this could reduce the time patients need platelet transfusions after a cord blood transplant, lowering infection and bleeding risks.
What could go wrong
This is a very early, small study (7 people) testing safety and feasibility. It may not show clear benefit, and there could be infusion reactions or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNACIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNACIES PLATELET RECOVERY AFTER UMBILICAL CORD BLOOD TRANSPLANTATION THROMBOCYTOPENIA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.